Atea Pharmaceuticals, Inc.

Contributing Author

Recent Articles by Atea Pharmaceuticals, Inc.

Jan-08	Atea Pharmaceuticals to Highlight 2026 Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference AVIR GlobeNewswire
Jan-06	Atea Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference AVIR GlobeNewswire
Dec-22	Atea Pharmaceuticals Completes Patient Enrollment in North American Phase 3 Trial Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus AVIR GlobeNewswire
Nov-19	Atea Pharmaceuticals to Present at the 8th Annual Evercore Healthcare Conference AVIR GlobeNewswire
Nov-12	Atea Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update AVIR GlobeNewswire
Nov-07	Atea Pharmaceuticals Presents New Data Supporting the Fixed-Dose Combination of Bemnifosbuvir and Ruzasvir as a Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Liver Meeting 2025 AVIR GlobeNewswire
Nov-05	Atea Pharmaceuticals to Host Third Quarter 2025 Financial Results and Business Update Conference Call on November 12, 2025 AVIR GlobeNewswire
Oct-22	Atea Pharmaceuticals to Host Virtual HCV KOL Panel Event on November 13, 2025 AVIR GlobeNewswire
Oct-07	Atea Pharmaceuticals to Present New Data Supporting Combination of Bemnifosbuvir and Ruzasvir as Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Liver Meeting 2025 AVIR GlobeNewswire
Sep-02	Atea Pharmaceuticals to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference AVIR GlobeNewswire
Aug-07	Atea Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update AVIR GlobeNewswire
Jul-31	Atea Pharmaceuticals to Host Second Quarter 2025 Financial Results and Business Update Conference Call on August 7, 2025 AVIR GlobeNewswire
Jun-24	Atea Pharmaceuticals Announces Continued Advancement of Global Phase 3 HCV Program with Dosing of First Patient in C-FORWARD Outside North America AVIR GlobeNewswire
May-12	Atea Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update AVIR GlobeNewswire
May-07	Atea Pharmaceuticals Announces Full Results from Phase 2 Study of Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus (HCV) Presented at EASL Congress 2025 AVIR GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved.